SLC5A2 and heart failure: The latest drugs used in the treatment of heart failure patients, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, were not included in this study as they were first approved only for diabetic patients and significantly after ARNI for heart failure patients.